Stockscreener 앱 받기
187.06
1.17%
-2.22
Biogen Inc 주식(BIIB)의 최신 뉴스
Mitsubishi UFJ Trust & Banking Corp Cuts Stake in Biogen Inc. $BIIB - MarketBeat
Artemis Investment Management LLP Buys Shares of 226,845 Biogen Inc. $BIIB - MarketBeat
Freedom Broker upgrades Biogen stock rating on Apellis acquisition By Investing.com - Investing.com Canada
Citigroup Adjusts Biogen Price Target to $200 From $190 - marketscreener.com
H.C. Wainwright reiterates Biogen stock rating on tau therapy trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Goldman Sachs Adjusts Biogen Price Target to $250 From $238 - marketscreener.com
Biogen Analysts Boost Their Forecasts Following Upbeat Q1 Earnings - Benzinga
Analysts Conflicted on These Healthcare Names: CareDx (CDNA), Biogen (BIIB) and Guardant Health (GH) - The Globe and Mail
Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim raises Biogen stock price target to $260 on strong Q1 results - Investing.com
Biogen Inc. Stock (US09062X1037): Analyst Rating Changes and Q1 2026 Earnings Preview - AD HOC NEWS
Biogen (BIIB) One Off US$1.1b Loss Tests Bullish Earnings Growth Narrative - simplywall.st
Is Biogen (BIIB) 2.7% Undervalued After Q1 2026? Non-GAAP EPS $3 - GuruFocus
A Look at Biogen Inc (BIIB) After 6.0% Gain -- GF Value $199.82 vs Price $194.38 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard Capital Management (NASDAQ: BIIB) reports 10.99M Biogen shares ownership - Stock Titan
Biogen beats estimates as Alzheimer’s drug gains momentum - The Boston Globe
Biogen Inc. (BIIB.US) 1Q Earnings and Revenue Beat Forecasts - AASTOCKS.com
BofA raises Biogen stock price target on solid quarterly results - Investing.com
BofA raises Biogen stock price target on solid quarterly results By Investing.com - Investing.com Canada
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Biogen Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biogen Q1 2026 slides: EPS beats forecast, Apellis deal to boost growth - Investing.com
Biogen Q1 Earnings Call Highlights - Yahoo Finance
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs - Yahoo Finance
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge - TechStock²
Earnings call transcript: Biogen Q1 2026 beats expectations with strong EPS and revenue growth - Investing.com
Biogen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Biogen (BIIB) Reports Strong Q1 Earnings, Raises 2026 EPS Guidan - GuruFocus
Biogen Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BIIB) 2026-04-29 - Seeking Alpha
Biogen (BIIB) Projects Revenue Decline and Adjusts EPS Forecast for 2026 - GuruFocus
Biogen cuts annual profit forecast on acquisition-related charges - marketscreener.com
Biogen Inc. (BIIB) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Biogen Q1 Non-GAAP Earnings, Revenue Rise; Cuts 2026 Earnings Outlook - marketscreener.com
Biogen (NASDAQ: BIIB) boosts profit and cash flow, plans $5.6B Apellis buy - Stock Titan
Biogen posts Q1 beat, trims earnings outlook (BIIB:NASDAQ) - Seeking Alpha
Biogen (NASDAQ:BIIB) Surprises With Q1 CY2026 Sales - Yahoo Finance
Apellis deal and Q1 2026 results reshape Biogen (NASDAQ: BIIB) outlook - Stock Titan
Biogen : BIIB Q1 26 Earnings Presentation Final - marketscreener.com
Biogen : Q1 2026 Earnings Press Release Final - marketscreener.com
Biogen posts Q1 revenue of $2.5B, surpasses estimates - Breakingthenews.net
Biogen Beats Estimates as Alzheimer’s Drug Gains Momentum - Bloomberg.com
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Biogen Q1 2026 earnings preview - MSN
Eyes on Asia: Takesa, Daiichi Sankyo, Biogen - BioXconomy
Is Biogen (BIIB) Still Attractive After Recent Share Price Rebound And DCF Upside Estimate - simplywall.st
Truist reiterates Hold on Biogen stock ahead of tau therapy data - Investing.com Australia
Biogen is entitled to damages in Tecfidera case rules Regional Court Hamburg - JUVE Patent
BIIB (Biogen) Total Payout Yield % : 0.00 (As of May. 01, 2026) - GuruFocus
Biogen Inc. (BIIB) Gets Upgraded by UBS on Upcoming Pipeline Catalysts - Yahoo Finance
Emerging Sub-Segments Transforming the Avonex Market Landscape - openPR.com
Apellis surges on $5.6B buyout deal with Biogen - MSN
AEGON ASSET MANAGEMENT UK Plc Raises Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Buyout Bet On Felzartamab: A Hidden Blockbuster In The Making? - Smartkarma
The Goldman Sachs Group Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $21.83 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
Should Biogen’s (BIIB) Full Global Control of Felzartamab Require Action From Investors? - simplywall.st
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
BofA raises Biogen stock price target to $200 on base business - Investing.com
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal - Yahoo Finance
Goldman Sachs Adjusts Price Target on Biogen to $238 From $231, Maintains Buy Rating - marketscreener.com
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
1.39%
0.62%
자본화:
|
볼륨(24시간):